RU2020115915A3 - - Google Patents

Download PDF

Info

Publication number
RU2020115915A3
RU2020115915A3 RU2020115915A RU2020115915A RU2020115915A3 RU 2020115915 A3 RU2020115915 A3 RU 2020115915A3 RU 2020115915 A RU2020115915 A RU 2020115915A RU 2020115915 A RU2020115915 A RU 2020115915A RU 2020115915 A3 RU2020115915 A3 RU 2020115915A3
Authority
RU
Russia
Application number
RU2020115915A
Other languages
Russian (ru)
Other versions
RU2020115915A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020115915A publication Critical patent/RU2020115915A/ru
Publication of RU2020115915A3 publication Critical patent/RU2020115915A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2020115915A 2017-10-31 2018-10-30 Бициклические сульфоны и сульфоксиды и способы их применения RU2020115915A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579392P 2017-10-31 2017-10-31
US62/579,392 2017-10-31
PCT/EP2018/079772 WO2019086494A1 (en) 2017-10-31 2018-10-30 Bicyclic sulfones and sulfoxides and methods of use thereof

Publications (2)

Publication Number Publication Date
RU2020115915A RU2020115915A (ru) 2021-12-01
RU2020115915A3 true RU2020115915A3 (https=) 2022-05-06

Family

ID=64051580

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020115915A RU2020115915A (ru) 2017-10-31 2018-10-30 Бициклические сульфоны и сульфоксиды и способы их применения

Country Status (21)

Country Link
US (2) US11072617B2 (https=)
EP (1) EP3704097B1 (https=)
JP (1) JP2021501183A (https=)
KR (1) KR20200083515A (https=)
CN (1) CN111278809B (https=)
AR (1) AR113811A1 (https=)
AU (1) AU2018360270A1 (https=)
BR (1) BR112020008446A2 (https=)
CA (1) CA3078688A1 (https=)
CL (1) CL2020001062A1 (https=)
CO (1) CO2020003475A2 (https=)
CR (1) CR20200168A (https=)
IL (1) IL273847A (https=)
MA (1) MA50503A (https=)
MX (1) MX2020003451A (https=)
PE (1) PE20211247A1 (https=)
PH (1) PH12020550537A1 (https=)
RU (1) RU2020115915A (https=)
SG (1) SG11202002877RA (https=)
TW (1) TW201922748A (https=)
WO (1) WO2019086494A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ripk1抑制劑之異㗁唑啶及其用途
WO2023083847A1 (en) 2021-11-11 2023-05-19 Sanofi Isoxazolidines as ripk1 inhibitors and use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) * 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) * 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
ATE410161T1 (de) 2003-05-02 2008-10-15 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
RU2628616C2 (ru) 2011-11-03 2017-08-21 Ф. Хоффманн-Ля Рош Аг Бициклические соединения пиперазина
EP2852584B1 (en) 2012-05-22 2018-02-28 F. Hoffmann-La Roche AG Substituted dipyridylamines and uses thereof
CA2896187A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
PH12019502378A1 (en) 2013-05-01 2022-05-11 Hoffmann La Roche Biheteroaryl compounds and uses thereof
WO2015006280A1 (en) 2013-07-10 2015-01-15 Vertex Pharmaceuticals Incorporated Fused piperidine amides as modulators of ion channels
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
WO2017109724A1 (en) * 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
MA44007A (fr) * 2016-02-05 2018-12-19 Denali Therapeutics Inc Inhibiteurs du récepteur interagissant avec protéine kinase 1
US11180493B2 (en) 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
PE20211246A1 (es) 2017-10-11 2021-07-13 Hoffmann La Roche Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof

Also Published As

Publication number Publication date
EP3704097B1 (en) 2023-10-25
EP3704097C0 (en) 2023-10-25
IL273847A (en) 2020-05-31
CN111278809A (zh) 2020-06-12
EP3704097A1 (en) 2020-09-09
AU2018360270A1 (en) 2020-03-26
US11072617B2 (en) 2021-07-27
JP2021501183A (ja) 2021-01-14
AR113811A1 (es) 2020-06-10
SG11202002877RA (en) 2020-04-29
KR20200083515A (ko) 2020-07-08
MA50503A (fr) 2020-09-09
BR112020008446A2 (pt) 2020-12-29
RU2020115915A (ru) 2021-12-01
CA3078688A1 (en) 2019-05-09
US20230002391A1 (en) 2023-01-05
CL2020001062A1 (es) 2020-08-21
MX2020003451A (es) 2020-08-03
PE20211247A1 (es) 2021-07-13
US20190127382A1 (en) 2019-05-02
WO2019086494A1 (en) 2019-05-09
CR20200168A (es) 2020-07-12
US12338241B2 (en) 2025-06-24
CN111278809B (zh) 2024-06-25
TW201922748A (zh) 2019-06-16
CO2020003475A2 (es) 2020-04-24
PH12020550537A1 (en) 2021-03-22

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BE2017C035I2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR102017003115A2 (https=)
BR202017002826U2 (https=)
CN304002283S (https=)
CN303892650S8 (https=)
CN303997352S (https=)
CN303997459S (https=)
CN303993892S (https=)
CN303992828S (https=)